It is important for people with diabetes to manage blood sugars and avoid high glycemic levels (hyperglycemia) to avoid dangerous and debilitating long term conditions including heart disease, stroke, high blood pressure, blindness, kidney disease, amputations, dental diseases, pregnancy complications, sexual dysfunction, and nervous system disease (1). It is also crucial to avoid dangerously low glycemic levels (hypoglycemia), which are associated with acute cognitive dysfunctions like blurred vision, irritability, dizziness, and even loss of consciousness or death.

Current treatments, which are based on conventional self monitoring blood glucose (SMBG) methods, only approximate the function of the normal pancreas and the blood glucose profiles of even the most diligent individuals can remain markedly abnormal. Studies of glycemic variability indicate that even brief hyper- and hypoglycemia may have profound detrimental effects. Without the means for reliable, convenient continuous glucose monitoring needed to optimize care, many individuals may experience periods of hyperglycemia and hypoglycemia, increasing both short term and long term health risks. Patients and caregivers face a delicate balancing act to maintain glycemic control. A constant dilemma is that their efforts to prevent complications by avoiding hyperglycemia can increase the risk for dangerous hypoglycemia. The GlySens CGM system is intended to help alleviate the worries that can accompany such efforts to improve glucose control.

Current “needle-sensor” products last for up to 14 days before requiring at-home removal and reinsertion of a new sensor. Newly available implantable sensors only last up to 3 months, requiring a Health Care Professional and an office visit. In contrast, the GlySens fully implanted sensor is being designed to last for up to 2-years without user intervention and only require a brief outpatient procedure every 2 years. A truly Long-Term sensor enables individuals to worry less about their diabetes devices.

Through-the-skin and on-the-skin components like needle-sensors and transmitters, are viewed by many as problematic for daily as well as active lifestyles. They are uncomfortable, burdensome and can hinder daily activity. In contrast, the GlySens sensor is fully implanted and designed to eliminate the visible body burden of current diabetes technology thereby enabling individuals to live their most uncompromising and healthiest life.

Short-Term sensors require an individuals' constant cognitive attention to ensure success. Routine decisions like renewing a sensor after expiration, daily maintenance and reapplication of adhesive or multi-day finger stick calibrations often impact long-term use. On the contrary, the Eclipse 3 System is designed to eliminate these barriers and enable 100% adherence, thereby reducing the cognitive demands of diabetes devices and enabling positive health benefits.

© 2021 GlySens Incorporated. All Rights Reserved.
CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use.
GlySens® and Eclipse® are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.